275 related articles for article (PubMed ID: 32526907)
1. Identifying and Overcoming Mechanisms of PARP Inhibitor Resistance in Homologous Recombination Repair-Deficient and Repair-Proficient High Grade Serous Ovarian Cancer Cells.
Gomez MK; Illuzzi G; Colomer C; Churchman M; Hollis RL; O'Connor MJ; Gourley C; Leo E; Melton DW
Cancers (Basel); 2020 Jun; 12(6):. PubMed ID: 32526907
[TBL] [Abstract][Full Text] [Related]
2. Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint.
Lin X; Chen D; Zhang C; Zhang X; Li Z; Dong B; Gao J; Shen L
J Exp Clin Cancer Res; 2018 Jun; 37(1):129. PubMed ID: 29954437
[TBL] [Abstract][Full Text] [Related]
3. Radiosensitization by the PARP inhibitor olaparib in BRCA1-proficient and deficient high-grade serous ovarian carcinomas.
Bi Y; Verginadis II; Dey S; Lin L; Guo L; Zheng Y; Koumenis C
Gynecol Oncol; 2018 Sep; 150(3):534-544. PubMed ID: 30025822
[TBL] [Abstract][Full Text] [Related]
4. Breaking the Iron Homeostasis: A "Trojan Horse" Self-Assembled Nanodrug Sensitizes Homologous Recombination Proficient Ovarian Cancer Cells to PARP Inhibition.
Li Y; Cen Y; Fang Y; Tang S; Li S; Ren Y; Zhang H; Lu W; Xu J
ACS Nano; 2022 Aug; 16(8):12786-12800. PubMed ID: 35920396
[TBL] [Abstract][Full Text] [Related]
5. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
[TBL] [Abstract][Full Text] [Related]
6. Activation of Wnt signaling promotes olaparib resistant ovarian cancer.
Yamamoto TM; McMellen A; Watson ZL; Aguilera J; Ferguson R; Nurmemmedov E; Thakar T; Moldovan GL; Kim H; Cittelly DM; Joglar AM; Brennecke EP; Wilson H; Behbakht K; Sikora MJ; Bitler BG
Mol Carcinog; 2019 Oct; 58(10):1770-1782. PubMed ID: 31219654
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of WEE1 Potentiates Sensitivity to PARP Inhibitor in Biliary Tract Cancer.
Seo HR; Nam AR; Bang JH; Oh KS; Kim JM; Yoon J; Kim TY; Oh DY
Cancer Res Treat; 2022 Apr; 54(2):541-553. PubMed ID: 34352995
[TBL] [Abstract][Full Text] [Related]
8. Homologous recombination deficiency and ovarian cancer.
Ledermann JA; Drew Y; Kristeleit RS
Eur J Cancer; 2016 Jun; 60():49-58. PubMed ID: 27065456
[TBL] [Abstract][Full Text] [Related]
9. Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.
Parkes EE; Kennedy RD
Oncologist; 2016 May; 21(5):586-93. PubMed ID: 27022037
[TBL] [Abstract][Full Text] [Related]
10. Cediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancer.
Ivy SP; Liu JF; Lee JM; Matulonis UA; Kohn EC
Expert Opin Investig Drugs; 2016; 25(5):597-611. PubMed ID: 26899229
[TBL] [Abstract][Full Text] [Related]
11. Advances in the use of PARP inhibitor therapy for breast cancer.
McCann KE; Hurvitz SA
Drugs Context; 2018; 7():212540. PubMed ID: 30116283
[TBL] [Abstract][Full Text] [Related]
12. Clinical Implications of DNA Repair Defects in High-Grade Serous Ovarian Carcinomas.
Milanesio MC; Giordano S; Valabrega G
Cancers (Basel); 2020 May; 12(5):. PubMed ID: 32455819
[TBL] [Abstract][Full Text] [Related]
13. Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials.
Yuan B; Ye N; Song SS; Wang YT; Song Z; Chen HD; Chen CH; Huan XJ; Wang YQ; Su Y; Shen YY; Sun YM; Yang XY; Chen Y; Guo SY; Gan Y; Gao ZW; Chen XY; Ding J; He JX; Zhang A; Miao ZH
Cancer Lett; 2017 Feb; 386():47-56. PubMed ID: 27847302
[TBL] [Abstract][Full Text] [Related]
14. Synergism of PARP inhibitor fluzoparib (HS10160) and MET inhibitor HS10241 in breast and ovarian cancer cells.
Han Y; Chen MK; Wang HL; Hsu JL; Li CW; Chu YY; Liu CX; Nie L; Chan LC; Yam C; Wang SC; He GJ; Hortobagyi GN; Tan XD; Hung MC
Am J Cancer Res; 2019; 9(3):608-618. PubMed ID: 30949414
[TBL] [Abstract][Full Text] [Related]
15. BRCA Status Does Not Predict Synergism of a Carboplatin and Olaparib Combination in High-Grade Serous Ovarian Cancer Cell Lines.
Shen YT; Evans JC; Zafarana G; Allen C; Piquette-Miller M
Mol Pharm; 2018 Jul; 15(7):2742-2753. PubMed ID: 29750868
[TBL] [Abstract][Full Text] [Related]
16. Prexasertib, a cell cycle checkpoint kinases 1 and 2 inhibitor, increases
Brill E; Yokoyama T; Nair J; Yu M; Ahn YR; Lee JM
Oncotarget; 2017 Dec; 8(67):111026-111040. PubMed ID: 29340034
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic targeting and patient selection for cancers with homologous recombination defects.
Talens F; Jalving M; Gietema JA; Van Vugt MA
Expert Opin Drug Discov; 2017 Jun; 12(6):565-581. PubMed ID: 28425306
[TBL] [Abstract][Full Text] [Related]
18. Effects of Wee1 inhibitor adavosertib on patient-derived high-grade serous ovarian cancer cells are multiple and independent of homologous recombination status.
Roering P; Siddiqui A; Heuser VD; Potdar S; Mikkonen P; Oikkonen J; Li Y; Pikkusaari S; Wennerberg K; Hynninen J; Grenman S; Huhtinen K; Auranen A; Carpén O; Kaipio K
Front Oncol; 2022; 12():954430. PubMed ID: 36081565
[TBL] [Abstract][Full Text] [Related]
19. An Overview of PARP Resistance in Ovarian Cancer from a Molecular and Clinical Perspective.
Cordani N; Bianchi T; Ammoni LC; Cortinovis DL; Cazzaniga ME; Lissoni AA; Landoni F; Canova S
Int J Mol Sci; 2023 Jul; 24(15):. PubMed ID: 37569269
[TBL] [Abstract][Full Text] [Related]
20. CDK9 inhibitor CDKI-73 is synergetic lethal with PARP inhibitor olaparib in BRCA1 wide-type ovarian cancer.
Li J; Zhi X; Chen S; Shen X; Chen C; Yuan L; Guo J; Meng D; Chen M; Yao L
Am J Cancer Res; 2020; 10(4):1140-1155. PubMed ID: 32368391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
